title: The Food and Drug Administration's use of postmarketing (Phase IV) study requirements: exception to the rule?
authors.affiliation: Wolf, Greenfield & Sacks, P.C., USA.
authors.forename: Charles
authors.initials: C
authors.lastname: Steenburg
mesh_terms: D019380:Anti-HIV Agents; D017327:Clinical Trials, Phase IV as Topic / Q000331:legislation & jurisprudence; D020372:Dexfenfluramine; D017277:Drug Approval / Q000266:history / Q000331:legislation & jurisprudence / Q000379:methods; D049673:History, 20th Century; D007783:Lactones; D011358:Product Surveillance, Postmarketing / Q000639:trends; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D019380:Anti-HIV Agents; D007783:Lactones; D020372:Dexfenfluramine